_parp-inhibitors-revolutionising-cancer-treatment-preview-1.jpg "PARP Inhibitors: Revolutionising Cancer Treatment from parp Video Screenshot Preview 1")
Gallery_parp-inhibitors-revolutionising-cancer-treatment-preview-3.jpg "PARP Inhibitors: Revolutionising Cancer Treatment from parp Video Screenshot Preview 3")
Gallery_parp-inhibitors-revolutionising-cancer-treatment-preview-hqdefault.jpg "PARP Inhibitors: Revolutionising Cancer Treatment from parp Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 1 minute 11 seconds
👁 View: 4.9K times
Play Audio:👁 View: 4.9K times
Description:
astrazeneca
astrazeneca
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_personalizing-advanced-ovarian-cancer-treatment-with-parp-inhibitors-and-novel-approaches.webp "PeerView Oncology")
⏲ 57 minutes 11 seconds 👁 2.5K
_bono-parp-qu-tan-caro-est2024-gus-lucioni.webp "Gustavo Lucioni")
_susana-m-campos-md-mph-on-the-role-of-parp-inhibitors-in-the-treatment-landscape-of-ovarian-cancer.webp "Susana M. Campos, MD, MPH, of Dana-Farber Cancer Institute, discusses recent changes to the NCCN Ovarian Cancer Guidelines and the implications for treatment going forward.")
⏲ 1 min 37 sec ✓ 26-Apr-2018
_parp-inhibitors-for-the-treatment-of-ovarian-cancer-gottfried-konecny-md-124-uclamdchat.webp "UCLA Health")
⏲ 34 minutes 17 seconds 👁 4.6K
_linda-mileshkin-mbbs-on-solid-tumors-early-treatment-study-results.webp "Linda Mileshkin, MBBS, of the Peter MacCallum Cancer Centre, discusses phase Ib trial findings on the anti–PD-1 monoclonal antibody BGB-A317 in combination with the PARP inhibitor BGB-290 in advanced solid tumors.")
_an-overview-of-parp-inhibitors-in-ovarian-cancer.webp "Targeted Oncology")
_parp-inhibitors-for-ovarian-cancer.webp "VJOncology")
_joshua-m-lang-md-on-prostate-cancer-best-of-the-journals.webp "Joshua M. Lang, MD, of the University of Wisconsin Carbone Cancer Center, discusses genomic alterations in DNA damage–repair pathways––more common in patients with prostate cancer than previously recognized–– and clinical trials with PARP inhibitors.")
_personalizing-advanced-ovarian-cancer-treatment-with-parp-inhibitors-and-novel-approaches.jpg)
_bono-parp-qu-tan-caro-est2024-gus-lucioni.jpg)
_susana-m-campos-md-mph-on-the-role-of-parp-inhibitors-in-the-treatment-landscape-of-ovarian-cancer.jpg)
_parp-inhibitors-for-the-treatment-of-ovarian-cancer-gottfried-konecny-md-124-uclamdchat.jpg)
_linda-mileshkin-mbbs-on-solid-tumors-early-treatment-study-results.jpg)
_an-overview-of-parp-inhibitors-in-ovarian-cancer.jpg)
_parp-inhibitors-for-ovarian-cancer.jpg)
_joshua-m-lang-md-on-prostate-cancer-best-of-the-journals.jpg)
![[+]](/images/menu.gif){kind=small}